• Alps Group launched a Pharmaco-Interaction laboratory unit at its MyGenome subsidiary in Kuala Lumpur, Malaysia, expanding its commercial testing services.
• The unit debuts with CYP450 inhibitory IC50 testing for drug interactions, targeting herbal and supplement manufacturers, pharmaceutical companies and research institutions.
• Testing covers seven major enzyme isoforms responsible for metabolizing approximately 90% of marketed clinical drugs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alps Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-051236), on November 12, 2026, and is solely responsible for the information contained therein.